Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AUSTIN HOW MANY SHARES ARE YU SHORT AND WHAT PRICE??
So NWBO did not provide 5MM worth of NWBO shares to Malik but Toucan did from it's own share and warrant holding. Even if we assume Tucan did this as a payment to pump the stock, this is not an issue for NWBO. Tucan is not NWBO. They are only shareholders.
I believe you are correct on this! I dont believe they would pay him 2 yrs later for a story! Thats flat stupid
The company did respond to certain allegations, but conveniently stayed silent on others. They are not transparent and there is no excuse for it. There should be independent non-executive directors as Woodford pointed out, which creates checks and balances throughout everything that is done.
So one), they can't ring the bell or shut from the rooftops anyway, until two) the process is completed. And three) they plan to report it.
I doubt Woodford would go through any of this if he had no faith in NWBO. It's because he does have faith that he is moving to protect his and the company's interest.
I could say you did some improper things anonymously. How would that hold up for you even if you were an upstanding citizen?
It is amazing right?
Happy Birthday! Senti and Evaluate
and a Happy Thanksgiving for the rest of us.
I read it several times, but I am having trouble understanding this:
PS although "having no foundation or basis in fact" is the definition, the synonyms include unsubstantiated, unproven, unsupported, uncorroborated, unconfirmed, unverified, unattested. This would suggest they aren't baseless, but need to substantiated or unsubstantiated.
unfounded - (adjective) without foundation; not based on fact, realistic considerations, or the like
baseless - (adjective) having no base; without foundation; groundless: a baseless claim.
unsubstantiated - (adjective) not substantiated; unproved or unverified
You have obviously seen our recent filing to the SEC and we are unable to comment further at this stage. Suffice to say that we believe in robust and transparent corporate governance and the filing has been made to protect the interests of shareholders by investigating and reporting on serious, but unfounded, allegations that suggest otherwise."
How many shares are you long, and at what price.
Be transparent.
And who is Austin? Why not reply to poster if you are addressing him..
Mods, feel free to delete this post. Generally only posts about short side motives are allowed.
I don't speak Spanish but somehow I know exactly what that means and I agree wholeheartedly. lol.
Are you kidding me?!?!?!? Are you saying the author of the PhaseV report added the disclosure to the report bashing NWBO? You've got to be kidding!
AUSTIN HOW MANY SHARES ARE YU SHORT AND WHAT PRICE??
BE TRANSPARENT ............
In case anyone... as I did... mistakenly thinks the disclaimer is part of any article written by Malik or Cenkos, IT IS NOT.
the disclaimer
"The firm admits in its disclaimer that when it publishes any report on its site, it should be assumed that the company, employees and clients have taken an investment position in the stock, be that a long or short bet, "and therefore stands to realize significant gains in the event that the price of the stock increases or declines".
GGB~
Tortuga no comprende ingles...el esta loco
HAPPY THANKSGIVING TO YOU ALL
Thx Neil for pressuring these jerks !!!
Finally Woody is feeling like me.... Something is seriously wrong here with NWBO.
Thx Neil for pressuring these jerks !!!
Our research has uncovered that Dr. Navid Malik, NWBO's 2012 nominated independent director, released in 2010 a very bullish research report on NWBO. Shortly after, a company he had just incorporated in Delaware received approximately $5 million worth of shares and warrants of NWBO from Powers' Toucan Fund II vehicle, shares that were subsequently sold by the company.
I disagree. I bet if you think about it, you do too.
Trial results are not impervious to false attacks. Can you imagine the BOD and investors for a biotech stating, "Ah Jeez, just let the shorts flood the airwaves with false attacks and lower how the public perceives us....we'll just nail em with significant results and that will undo all the damage, delay, expense and other crap they are throwing at us."
No, it is wise for NW to protect shareholders regardless if he knows whether we (might) have great results or not. Besides, the idea behind his Patient Investor Fund is that he invests in companies with great scientists and science, and his group can provide small biotech's business consulting and resources to successfully get from trial to commercialization.
Please remember, there was a time when everything Adam had ever brought up was addressed by the company in a separate PR. There were some on this board that agreed with this policy (that would include me), and there some on this board that absolutely did not. They were very, very vocal about not agreeing with that policy.
Anyhow... it doesn't matter. They can hardly address anything at this time. Maybe it's best to just spring it on us all at once. You know, ring the bell so loudly that it echoes for a while.
Plus there's that bit from the August 25 8-K...
A shareholder inquiry also asked what information the Company is submitting to regulators. The Company’s response noted that such submissions would not normally be discussed in the middle of a regulatory process or dialog, and that the Company plans to report when the process has been completed.
Thanks, TC. Nothing beats going to the source.
I doubt Woodford would go through any of this if he had no faith in NWBO. It's because he does have faith that he is moving to protect his and the company's interest.
Thanksgiving is upon us but I will say one more thing.
Let the short hedge fund make the allegation. Staying anonymous is cowardly. You have lawyers. Buck up and grow a pair.
Your lawyers probably say no. Wonder why?
He probably knew the whole situation with these allegations prior to putting his nominee up.
I think he has gotten concerns from shareholders of his fund since they made a point of bringing Woodford's holdings in the company in the article this past weekend regarding Malik suspension. Probably what prompted a more public communication on the matter. I suspect he was already discussing it before that since he referenced a discussion on Nov 13 and interview with candidate last week. I would not read anything regarding trial news (or lack thereof) into it.
Yup. And I will make my allegations from the Crimea where you can't come after me for securities manipulation on the short side.
I interpret it as investigating NWBO. It strikes me as being pretty straight forward.
The question to ask might be if Woodford still felt positive about the trial results why would he be compelled to "protect" his shareholders at this particular time. At the very least it probably means that he knows of no positive trial news forthcoming.
That's a very good question indeed :)
Hey Dude:
I could say you did some improper things anonymously. How would that hold up for you even if you were an upstanding citizen?
I think Marion is just the guy hosting the website in Romania. Not necessarily part of Phase V. --- Kap10jak
I think Marion is just the guy hosting the website in Romania. Not necessarily part of Phase V.
Dude, Phase V is a rag blog analysis company. Nobody said otherwise, and unfortunately they're not a publicly traded company that is held to higher standards. NWBO however is.
the link in post 45435 did not work for me.
This one did:
http://s1.q4cdn.com/460208960/files/Nov-20-2015_NWBO_Zeng.pdf
which includes:
Update on Phase III of DCVax-L Trial
Recently, some blog articles and social media comments have misunderstanding and wrong reading of
the company ongoing Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM). As
such, the company issued a few news releases to clarify and confirm that the Phase III trial is ongoing
per the protocol.
According to our understanding, the company s Phase III trial of DCVax®-L for newly diagnosed GBM is
ongoing and the patients enrolled in the trial are continuing to be treated per the protocol.
The only change in status of the trial is that new screening of patient candidates for the trial has been
temporarily suspended while the Company submits certain information from the trial for regulatory review.
Such screening involves the initial evaluation of patient candidates to determine whether they meet
eligibility criteria for the trial (e.g., whether they are within the eligible age range, do not have certain viral
diseases, etc.). The Company is in the process of preparing the trial information for regulatory review and
anticipates submission within the next couple of weeks.
The Phase III trial has reached late stage in patient enrollment. Currently there are more than 60 clinical
sites open and operating for the trial across the U.S. and in the U.K., Germany and Canada. The original trial plan involves enrollment of 312 total patients in the trial, and counting 110 events of
tumor recurrence or patient deaths from among these 312 patients to determine whether the primary
endpoint of the trial is met.
NWBO has modified its trial plan so that it will enroll 348 total patients, and will count 248 events from
among these 348 total patients to determine whether the primary endpoint of the trial is met. So, the
Zacks Investment Research Page 7 scr.zacks.com
number of events counted in the statistical analysis will increase from 110 to 248, but the total
enrollment in the trial will only increase from 312 to 348.
So far, over 300 patients have been recruited and treated in the trial. And, none of these 300 patients
are in the information arm or the pseudo-progression arm, each of which is parallel with the trial but
outside the trial. As far as what information the Company is submitting to regulators, the company responded that such
submissions would not normally be discussed in the middle of a regulatory process or dialog, and that the
Company plans to report when the process has been completed. This is in accordance with the industry
standard in our view.
Even with the screening delay, we still anticipate that the Phase III trial will reach its first interim analysis
for efficacy in late 2015 or early 2016 and anticipates that the Phase III trial will reach its primary endpoint
PFS (progression free survival) in 2016, potentially in the spring or summer. According to this schedule,
we expect an NDA will be submitted in late 2016 and DCVax-L will be approved in 2H2017.
Romania
Sounds like a reliable source that wants to be transparent.
Phase V doesn't want to reveal their identity ... Diamondjim61
Austin, I have not agreed with all of you past postings, but I have to say, I do agree with your assessments of the current situation. I think in the end, it will be positive either way. Either Linda and company will be vindicated, or they will be found to be guilty as charged, and even Linda would have to admit she could not be an effective CEO going forward if that were the case. She is still a majority owner, and we know she is not stupid. She would have to step aside and I'm sure with Woodford's "assistance" find a replacement to carry things forward to realize the potential of her own investment.
So, either way this turns out, I think it will be positive in the end. Just don't know how much pain we endure in the interim. It certainly would help if they announce some positive news on one of the other fronts. News that cannot be disputed or twisted to the short's advantage. AA for L, EAMS stage 2 approval, German pricing resolved.... Come on Linda, give us something to tide us over here!!!
Don't get me wrong, I do believe that the shorts have and do manipulate stocks for their gain. I also believe the same for longs. I believe AF manipulates headlines and the truth to effect the share price but I also believe he has brought up valid points that have never been addressed.
The company is just as much at fault for not being transparent with it's shareholders. If the issues were addressed they would be put to bed and invalid moving forward. When they're not, you get this. Obviously Woodford feels the same.
It does not mean the other crap that has been going on here endlessly is not being reviewed.
You have obviously seen our recent filing to the SEC and we are unable to comment further at this stage. Suffice to say that we believe in robust and transparent corporate governance and the filing has been made to protect the interests of shareholders by investigating and reporting on serious, but unfounded, allegations that suggest otherwise."
I would think that is a big part of it. Why take a firm with strong FBI ties? I think Woodford and NWBO management has had enough. The last crap coming our way on the board member was from an anonymous source.
Oct. 19th PR said it:
and now we will have it! (transparency - don't miss it)
NW Bio noted that the Company's shares have experienced highly unusual trading activity since the September release of positive data, including especially on Friday, October 16, when more than 2.9 million NW Bio shares were traded, representing five times its recent average daily trading volume. The Company believes this activity is part of an ongoing effort to drive its stock price lower through an orchestrated campaign, including questionable short selling activity. The Company is intensifying its investigation and gathering of evidence.
I'm not sure of the truth or validity of this accusation but Phase V said;
Five million dollars' worth of securities transferred to a company incorporated by an analyst covering the share, turned director. Our research has uncovered that Dr. Navid Malik, NWBO's 2012 nominated independent director, released in 2010 a very bullish research report on NWBO. Shortly after, a company he had just incorporated in Delaware received approximately $5 million worth of shares and warrants of NWBO from Powers' Toucan Fund II vehicle, shares that were subsequently sold by the company. Malik's involvement with the company prior to his nomination as director has been concealed from investors and we question the legitimacy of this transaction and his independence as director.
Cenkos Securities plc., Research Division. He covers life sciences research. Dr. Malik served as the Head of Life Sciences Equity Research at Merchant Securities Limited, Research Division and Merchant Securities Group plc since September 2011. He was the Partner and Head of Life Sciences Research at Matrix Group Limited, Research Division. Dr. Malik served as the Senior Equity Analyst at Collins ...
Read Full Background
Yes, I continue to be impressed by the quality and openness of the Woodford organization. The publish the facts of their fund performance and portfolio movements every month. It's almost like the are the antithesis of NWBO's style. I'm glad we have Neil Woodfords direct engagement with the NWBO management team and his impetus to improve shareholder value. It may be painful for Linda and Les to open the kimono, but the time has come for more transparency if they want to "go big or go home"
Give it a rest. I don't think me or the share price could take anymore good news.
Thanks, TC. Is it possible you could ask them if they are planning a joint PR with NWBO to show a united front? Or any PR for that matter? It would be great to see them say to the world what they said to you in a private email.
No I am not invested with them. I just emailed their main contact address on their website. I however have been signed up as a professional investor through their website for a while with the email address I used to contact them. I don't think that has any bearing though, they are very responsive and clearly know how to run a business.
TC, thanks for contacting Woodford Funds and uncovering the fact that they, too, see these anonymous allegations as unfounded and are fighting back.
Can you tell us, can anyone contact them, or do you have to be invested to get a response? In other words, are you invested or do you have a paid subscription?
Thanks and have a great Thanksgiving.
Jail, for Adam F, Phase v and others, would be nice.
Followers
|
1626
|
Posters
|
|
Posts (Today)
|
139
|
Posts (Total)
|
701867
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |